Coccidioidomycosis natural history: Difference between revisions
Jump to navigation
Jump to search
Aditya Ganti (talk | contribs) |
Aditya Ganti (talk | contribs) |
||
| Line 19: | Line 19: | ||
===Prognosis=== | ===Prognosis=== | ||
The prognosis of Coccidioidomycosis is excellent. Most infections are self-limited and resolve without treatment | The prognosis of Coccidioidomycosis is excellent. Most infections are self-limited and resolve without treatment. <br> | ||
Factors associated with poor prognosis: | Factors associated with poor prognosis: | ||
*HIV disease,with low CD4 count (<250) | *HIV disease,with low CD4 count (<250) | ||
| Line 25: | Line 25: | ||
*Organ transplantation | *Organ transplantation | ||
*Immunosuppresant therapy <ref name="pmid15188373">{{cite journal |vauthors=Bergstrom L, Yocum DE, Ampel NM, Villanueva I, Lisse J, Gluck O, Tesser J, Posever J, Miller M, Araujo J, Kageyama DM, Berry M, Karl L, Yung CM |title=Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists |journal=Arthritis Rheum. |volume=50 |issue=6 |pages=1959–66 |year=2004 |pmid=15188373 |doi=10.1002/art.20454 |url=}}</ref> | *Immunosuppresant therapy <ref name="pmid15188373">{{cite journal |vauthors=Bergstrom L, Yocum DE, Ampel NM, Villanueva I, Lisse J, Gluck O, Tesser J, Posever J, Miller M, Araujo J, Kageyama DM, Berry M, Karl L, Yung CM |title=Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists |journal=Arthritis Rheum. |volume=50 |issue=6 |pages=1959–66 |year=2004 |pmid=15188373 |doi=10.1002/art.20454 |url=}}</ref> | ||
The mortality rate is very low (<0.07%). | The mortality rate is very low (<0.07%). | ||
==References== | ==References== | ||
Revision as of 20:02, 9 March 2017
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: ; Vidit Bhargava, M.B.B.S [2]
|
Coccidioidomycosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Coccidioidomycosis natural history On the Web |
|
American Roentgen Ray Society Images of Coccidioidomycosis natural history |
|
Risk calculators and risk factors for Coccidioidomycosis natural history |
Natural History
- Coccidioidomycosis is usually a self-limited mild clinical illness.
- A large proportion of individuals are clinically infected without any manifestations and are thus completely asymptomatic.
- The remaining develop a mild pulmonary illness which in most cases is self limited requiring no treatment, and even those cases which do require treatment have an excellent prognosis.
- It is often misdiagnosed as community-acquired pneumonia. There are several cutaneous manifestations such as erythema multiforme and erythema nodosum, it may even cause arthritis and arthralgias.
- If left untreated in patients with weakened immune systems,the infection spreads throughout the body.
- The disseminated form of Coccidioidomycosis can devastate the body, causing skin ulcers, abscesses, bone lesions, swollen joints with severe pain, heart inflammation, urinary tract problems, and inflammation of the brain's lining, which can lead to death.[1]
Complications
Complications of coccidioidomycosis include:[2][3]
- Pleural effusion
- Return of the infection (relapse
- Meningitis
- Pulmonary cavities, that may rupture leading to pyopneumothroax, otherwise causing persistent cough, hemoptysis, and pleuritic chest pain.
- Synovitis and Osteomyelitis.
Prognosis
The prognosis of Coccidioidomycosis is excellent. Most infections are self-limited and resolve without treatment.
Factors associated with poor prognosis:
- HIV disease,with low CD4 count (<250)
- Late stage Pregnancy( third trimester)
- Organ transplantation
- Immunosuppresant therapy [4]
The mortality rate is very low (<0.07%).
References
- ↑ Galgiani J. N. Coccidioidomycosis. In: Cecil, Russell L., Lee Goldman, and D. A. Ausiello. Cecil Medicine. Philadelphia: Saunders Elsevier, 2007.
- ↑ Angelo, KM.; Nnedu, ON. "Rare manifestations of coccidioidomycosis". J La State Med Soc. 165 (3): 137–9. PMID 24015425.
- ↑ Remesar, MC.; Blejer, JL.; Negroni, R.; Nejamkis, MR. "Experimental coccidioidomycosis in the immunosuppressed rat". Rev Inst Med Trop Sao Paulo. 34 (4): 303–7. PMID 1342086.
- ↑ Bergstrom L, Yocum DE, Ampel NM, Villanueva I, Lisse J, Gluck O, Tesser J, Posever J, Miller M, Araujo J, Kageyama DM, Berry M, Karl L, Yung CM (2004). "Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists". Arthritis Rheum. 50 (6): 1959–66. doi:10.1002/art.20454. PMID 15188373.